Sofosbuvir in Treatment of COVID 19

Official Title

Sofosbuvir Based Regimens in Treatment of COVID 19 Patients

Brief Summary

Sofosbuvir containing treatment in treatment of COVID 19 Egyptian patients

Detailed Description

Sofosbuvir containing treatment of COVID 19 Egyptian patients: a randomized-controlled trial

Status

Unknown status

Conditions

COVID

Interventions

Drug: sofosbuvir

Sofosbuvir once daily
Other Name: Mpiviropack, Sovaldy, soflanork

Drug: Sofosbuvir ledipsavir

Sofosbuvir ledipsavir once daily
Other Name: mpiviropack plus

Drug: Daclatasvir

Daklatasuvir tablets
Other Name: daklinza

Eligibility Criteria

Inclusion Criteria:

- Covid positive patients.

Exclusion Criteria:

- Contraindication to sofosbuvir or ribavirin.

Eligibility Gender

All

Eligibility Age

Minimum: N/A ~ Maximum: N/A

Countries

Egypt

Locations

Sherief Abd-Elsalam
Tanta, Egypt

Investigator: Sherief Abd-Elsalam, Ass. Prof.
Contact: 00201009221243
sheriefabdelsalam@yahoo.com

Contacts

Sherief Abd-Elsalam, ass. prof.
00201147773440
sheriefabdelsalam@yahoo.com

sherief abd-elsalan, ass. prof.
00201147773440
sheriefabdelsalam@yahoo.com

Investigators

Marwa Salama, Consultant, Principal Investigator
Tanta University - Faculty of Medicine

NCT Number

NCT04460443

MeSH Terms

Sofosbuvir

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Tanta University

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA